Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

lidERA Breast Cancer : A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Breast<br/>CancersCancer LocationBreast
Cancers

Systemic therapy,Treatment | BreastBreast

Trial Overview Read MoreRead more

This phase III trial is comparing the safety and effectiveness of a hormone therapy drug called Giredestrant with other types of hormone therapy for the treatment of stage 1-3 ER positive and HER2 negative breast cancer.
 

This trial is treating patients with ER positive and HER2 negative breast cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Commercial Sponsor

Hoffmann-La Roche

Summary

Eligible participants will be randomised to receive Giredestrant or a therapy of the physician's choice. Giredestrant will be administered as a 30mg orally, once a day on Days 1-28 of each 28-day cycle for 5-years or until disease recurrence or unacceptable toxicity occurs. The hormone therapy of physician's choice is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane.

Recruiting Hospitals Read MoreRead more

Ballarat Oncology & Haematology
Ballarat
Ms Rosemary Cotton
rosemaryc@ballaratoncology.com.au
03 5339 8000

Bendigo Hospital
Bendigo
Cancer Research
cancerresearch@bendigohealth.org.au
03 5454 8827

Border Medical Oncology
Albury
Ms Kate Oates
koates@bordermedonc.com.au
02 6064 1499

Box Hill Hospital Medical Oncology
Box Hill
Ms Karen Lim
karen.lim@monash.edu
03 9094 9564

Peninsula Health
Frankston
Ms Linda Raineri
lraineri@phcn.vic.gov.au
03 9784 7175

Goulburn Valley Health
Shepparton
Ms Carole Mott
oncologyclinicaltrials@gvhealth.org.au
(03) 5832 3777

Maroondah Hospital, Maroondah Breast Clinic
Ringwood East
Ms Karen Lim
karen.lim@monash.edu
03 9094 9564

Victorian Breast and Oncology Care
East Melbourne
Ms Kayte Robinson
kayte@vboc.com.au
03 9417 4666

South West Healthcare
Warrnambool
Kaye McDowall
swhct@swh.net.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next